Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic
— Financing brings total funds committed to date to >$95 million
— Proceeds support the STARLYS clinical trial evaluating targeted LTBR agonist MST-0312 in solid tumors, together with platform and pipeline activities in inflammatory diseases
— Expands the leadership team with exceptional development executives to propel the clinical advancement of the pipeline
Cambridge, UK, March 17, 2026 – Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory diseases, today announced the closing of a $40 million financing supported by leading life science investors SV Health Investors, Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (Google Ventures) and Northpond Ventures. The company also announced the appointment of Lindsey Rolfe, BSc, MBChB, MRCP, FFPM, as Chief Medical Officer and Pascal Merchiers, PhD, as Chief Development Officer.
